Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 5Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 52Hodgkin Disease 29Lymphoma 15Sarcoma 7Neoplasm Metastasis 7Uveal Melanoma 6Skin Neoplasms 6Neoplasms 5Leiomyosarcoma 5Solitary Fibrous Tumors 2Sarcoma, Synovial 2Neuroblastoma 2Hematologic Diseases 2HIV Infections 2Solid Tumor 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × Dacarbazine × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

GlaxoSmithKline

Phase 3 Completed
251 enrolled 21 charts
Dermatologic

Melanoma, Neoplasms

NCT00110994 2015-06-08

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Bayer

Phase 2 Completed
101 enrolled 21 charts
Dermatologic

Melanoma, Neoplasms

NCT00246012 2013-08-19

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Centocor, Inc.

Phase 1/2 Completed
144 enrolled 34 charts
Dermatologic

Melanoma, Neoplasms

NCT00003647 2008-07-25

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Vical

Phase 3 Completed
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡